Charles River Laboratories
CRL · NYSE
Bulios Fair Price
$215.7
25.4% downside
Current Price
$288.99
According to Bulios Fair Price, CRL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Charles River Laboratories International, Inc. (CRL) is an American company operating in the biotechnology and pharmaceutical research industry. The company specializes in providing preclinical and clinical services to pharmaceutical and biotechnology companies, academic institutions, and government organizations. Its services include drug testing, toxicity studies, pharmacokinetics, viral safety testing, genetic analysis, and other biological and chemical analyses. Charles River Laboratories has a broad portfolio of laboratory and clinical services that are crucial for the development of new drugs and treatment protocols. The company emphasizes quality, innovation, and ethical standards in its research and laboratory practices. It is recognized as a significant partner for the pharmaceutical and biotechnology sectors. Charles River Laboratories International, Inc. (CRL) shares are publicly traded on the stock exchange and may represent an attractive investment opportunity for investors monitoring the biotechnology and pharmaceutical industry and seeking investments in a company with a significant position in drug research and development.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Birgit Girshick
Employees
19,000
Headquarters
Wilmington
Upcoming events
Earnings
Upcoming earnings report